This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost
by Zacks Equity Research
Becton, Dickinson (BDX) receives a number of regulatory approvals of late.
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) makes a few lucrative acquisitions in recent times.
Medical Products Industry Outlook: Plenty of Upside Left
by Zacks Equity Research
The growing adoption of AI, Medical Mechatronics & Robotics has lent the Medical Products industry a competitive edge in the broader medical market.
Meridian Bioscience (VIVO) Tops Q1 Earnings Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 11.11% and -0.04%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Ericsson (ERIC) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ericsson (ERIC) is likely to report higher year-over-year revenues in the fourth quarter of 2018 on the back of healthy growth dynamics.
New Strong Buy Stocks for January 21st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Meridian Bioscience (VIVO) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 25.00% and 3.74%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Meridian Bioscience (VIVO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Meridian Bioscience (VIVO) Q3 Earnings Beat Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 5.88% and -0.42%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
MedTech Growing on Emerging Markets, M&A: Stocks to Buy
by Zacks Equity Research
Given the current lack of clarity, let???s concentrate on some powerful long-term tailwinds of the medical device industry like emerging market expansion, mergers & acquisitions (M&A), positive demographic trends and new product innovation.
Meridian (VIVO) Initiates illumigene CMV Trial, Shares Shine
by Zacks Equity Research
Solid share price rally following the news suggests that the latest development is likely to buoy Meridian's (VIVO) bottom line and enhance its illumigene platform.
MedTech Industry Outlook - July 2017
by Zacks Equity Research
The overall expectation is that President Trump's legislative change for MedTech will result in lower taxes and regulation for the industry as a whole.
Top Ranked Income Stocks to Buy for May 24th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 24th:
Top Ranked Momentum Stocks to Buy for May 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 22nd:
Top Ranked Income Stocks to Buy for May 18th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 18th:
Top Ranked Income Stocks to Buy for May 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 12th:
Meridian (VIVO) to Provide LeadCare Testing System in Africa
by Zacks Equity Research
Meridian Bioscience, Inc. (VIVO), a renowned life sciences company, recently signed an exclusive distribution agreement with Biofirm Technologies.
What Makes Meridian Bioscience (VIVO) a Strong Sell?
by Zacks Equity Research
Meridian Bioscience (VIVO), has witnessed a significant price decline and negative trend in earnings estimate revisions
Meridian Bioscience Partners MedCaptain, Expands in China
by Zacks Equity Research
Meridian Bioscience, Inc. (VIVO) announced that its Magellan Diagnostics business has signed a distribution agreement with China-based MedCaptain Medical Technology.